Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Recommendation of “Moderate Buy” by Analysts

Keros Therapeutics, Inc. (NASDAQ:KROS) has received a consensus rating of “Moderate Buy” from the fourteen brokerages that are presently covering the stock, Marketbeat.com reports. Six research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $42.33.

A number of research analysts have recently issued reports on KROS shares. BTIG Research cut Keros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, December 12th. TD Cowen cut Keros Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. HC Wainwright reduced their price objective on Keros Therapeutics from $47.00 to $40.00 and set a “buy” rating on the stock in a research note on Thursday, February 27th. Guggenheim reaffirmed a “neutral” rating on shares of Keros Therapeutics in a research note on Friday, January 17th. Finally, Piper Sandler cut their target price on Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating on the stock in a research note on Friday, January 17th.

Institutional Trading of Keros Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. FMR LLC lifted its holdings in Keros Therapeutics by 3.8% in the third quarter. FMR LLC now owns 4,899,134 shares of the company’s stock worth $284,493,000 after buying an additional 179,374 shares during the period. Vanguard Group Inc. lifted its holdings in Keros Therapeutics by 5.4% in the fourth quarter. Vanguard Group Inc. now owns 1,957,109 shares of the company’s stock worth $30,981,000 after buying an additional 100,691 shares during the period. Alkeon Capital Management LLC lifted its holdings in Keros Therapeutics by 18.7% in the third quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock worth $110,194,000 after buying an additional 298,694 shares during the period. Braidwell LP lifted its holdings in Keros Therapeutics by 167.9% in the fourth quarter. Braidwell LP now owns 1,894,439 shares of the company’s stock worth $29,989,000 after buying an additional 1,187,199 shares during the period. Finally, Darwin Global Management Ltd. lifted its holdings in Keros Therapeutics by 10.7% in the fourth quarter. Darwin Global Management Ltd. now owns 1,687,135 shares of the company’s stock worth $26,707,000 after buying an additional 163,403 shares during the period. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Keros Therapeutics Stock Down 4.6 %

KROS opened at $11.38 on Monday. The business’s fifty day simple moving average is $12.00 and its 200 day simple moving average is $38.38. Keros Therapeutics has a 52 week low of $9.77 and a 52 week high of $72.37. The stock has a market cap of $461.60 million, a PE ratio of -2.18 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($1.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.36) by $0.22. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm had revenue of $3.04 million for the quarter, compared to analysts’ expectations of $37.32 million. As a group, equities analysts anticipate that Keros Therapeutics will post -4.74 earnings per share for the current year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.